- Global Pharma News & Resources

Opioid-Induced Constipation - Pipeline Insight, 2019 -

The "Opioid-Induced Constipation - Pipeline Insight, 2019" drug pipelines has been added to's offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Opioid-Induced Constipation development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Opioid-Induced Constipation

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Opioid-Induced Constipation

The report assesses the active Opioid-Induced Constipation pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

  • Develco Pharma
  • Schweiz AG
  • Ironwood Pharmaceuticals Inc.
  • Shionogi & Co. Ltd.
  • Sucampo Pharmaceuticals Inc.
  • Synergy Pharmaceuticals Inc.

Topics Covered

1. Report Introduction

2. Opioid-Induced Constipation Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical & Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 22-Jan-2019